Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120426 | 1.00 | TSHR (0.56) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL6135142 | 1.00 | TSHR (0.56) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10684124 | 0.97 | TSHR (0.54) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10684133 | 0.97 | TSHR (0.54) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL12841102 | 0.93 | TSHR (0.50) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL13839948 | 0.87 | TSHR (0.45) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL46155 | 0.86 | TSHR (0.72) | TSHRCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL10689902 | 0.84 | CHRM2 (0.42) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10688813 | 0.84 | TSHR (0.42) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 | |
| SCHEMBL10688802 | 0.84 | TSHR (0.42) | TSHRALDH1A1LMNAALOX12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| US-9487510-B2 | Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr. Reeddy's Laboratories Ltd. (IN) | 2015-01-29 | — | — | US | disclosed |
| EP-1540388-B1 | RETARDER AND ELLIPTICAL POLARIZING PLATE | FUJIFILM CORP (JP) | 2012-06-06 | — | — | EP | disclosed |
| WO-2005003140-A1 | 4-OXO-4,7-DIHYDROTHIENO[2,3-B]PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | AGOURON PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-0817772-B1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER (US) | 2003-01-29 | — | — | EP | disclosed |
| CN-1369565-A | Process for preparing chiral substituted arylepoxyethane compounds and its biol by selective splitting of Aspergillus niger | SHANGHAI INST ORGANIC CHEM (CN) | 2002-09-18 | — | — | CN | disclosed |
| US-6110947-A | AN ANALGESIC AGENT FOR TREATING STROKE, ABDOMINAL PAIN; AS ANTIINFLAMMATORY, DIURETIC, ANESTHETIC OR NEUROPROTECTIVE AGENTS | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-5952369-A | ANALGESIC, TREATMENT FOR STROKE OR ABDOMINAL PAIN ASSOCIATED WITH FUNCTIONAL BOWEL DISEASE | PFIZER INC (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1996030339-A1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004161-A1 | 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents | ZC3HAV1, IRF3, BRD4 | TSHR 3008/4885ALDH1A1 943/4885LMNA 4708/4885 |
| US-20150031685-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | TSHR 679/4885ALDH1A1 816/4885LMNA 4524/4885 |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | TSHR 670/4885ALDH1A1 786/4885LMNA 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.